Table 1. Genotype distribution of the different polymorphisms in AML patients and normal control population investigated in the study and their association with AML susceptibility.
| Polymorphisms | AML n (%) | Controls n (%) | OR (95% CI) | p-Value |
|---|---|---|---|---|
| rs2853669 | ||||
| TT | 89 (39.38) | 373 (47.88) | ||
| TC | 99 (43.8) | 341 (43.77) | 1.21 (0.88 – 1.67) | 0.13 |
| CC | 38 (16.81) | 65(8.34) | 2.45 (1.54 – 3.88) | 0.00015 |
| TC + CC | 137 | 406 | 1.41 (1.04 – 1.91) | 0.01 |
| Total | 226 | 779 | ||
| rs10069690 | ||||
| CC | 118 (52.21) | 409 (53.32) | ||
| CT | 93 (41.15) | 319 (41.60) | 1.01 (0.74 – 1.37) | 0.5 |
| TT | 15 (6.63) | 39 (4.68) | 1.33 (0.71 – 2.5) | 0.22 |
| CT + TT | 108 | 358 | 1.04 (0.77 – 1.4) | 0.41 |
| Total | 226 | 767 | ||
| rs2736100 | ||||
| AA | 48 (21.23) | 201 (25.5) | ||
| AC | 113 (50) | 406 (51.53) | 1.16 (0.79 – 1.7) | 0.24 |
| CC | 65 (28.76) | 181 (22.97) | 1.5 (0.98 – 2.29) | 0.03 |
| AC + CC | 178 | 587 | 1.26 (0.88 – 1.81) | 0.1 |
| Total | 226 | 788 | ||
| rs4246742 | ||||
| TT | 156 (69.02) | 520 (66.41) | ||
| TA | 65 (28.76) | 240 (30.66) | 0.9 (0.65 – 1.25) | 0.29 |
| AA | 05 (2.21) | 23 (2.93) | 0.72 (0.27 – 1.93) | 0.35 |
| TA + AA | 70 | 263 | 0.88 (0.64 – 1.22) | 0.25 |
| Total | 226 | 783 |